Stock Analiz

Eton Pharmaceuticals, Inc. (ETON) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$5M, a net margin of -5.8%; the best year in this period was 2023 with -$936000.

Over the twelve months to September 30, 2026, revenue was $141M and net income $50M.

Free cash flow was $10M in fiscal 2025 and positive in 4 of the 8 years shown.

The diluted share count rose 319% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $95900020192020: $3900020202021: $22M20212022: $21M20222023: $32M20232024: $39M20242025: $80M2025$80M
Net income
2018: -$13M20182019: -$18M20192020: -$28M20202021: -$2M20212022: -$9M20222023: -$93600020232024: -$4M20242025: -$5M2025-$5M
Free cash flow
2018: -$8M20182019: -$19M20192020: -$22M20202021: -$5M20212022: $5M20222023: $7M20232024: $94300020242025: $10M2025$10M
EPS (diluted)
2018: $-5.8020182019: $-1.0320192020: $-1.3320202021: $-0.0820212022: $-0.3620222023: $-0.0420232024: $-0.1520242025: $-0.172025$-0.17

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$141M$80M$39M$32M$21M$22M$39000$959000—
Gross profit$98M$43M$23M$21M$14M$19M-$397000$506000—
Operating income$41M-$844000-$3M-$1M-$8M-$1M-$27M-$19M-$10M
Net income$50M-$5M-$4M-$936000-$9M-$2M-$28M-$18M-$13M
EPS (diluted)$1.50$-0.17$-0.15$-0.04$-0.36$-0.08$-1.33$-1.03$-5.80
R&D$10M$8M$3M$3M$4M$6M$14M$12M$6M
Revenue growth—+104.9%+23.3%+48.9%−2.7%+55879.5%−95.9%——

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$38M$11M$969000$7M$5M-$5M-$22M-$18M-$8M
Capital spending-$132000-$333000-$26000$0-$38000-$9000-$50000-$1M-$236000
Free cash flow$38M$10M$943000$7M$5M-$5M-$22M-$19M-$8M
Dividends paid—$0$0$0$0$0$0$0$0
Buybacks—————————
Stock-based pay$7M$6M$3M$3M$4M$3M$3M$2M$2M

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$26M$15M$21M$16M$14M$21M$12M$27M
Debt—$31M$30M$5M$6M$5M$7M$5M—
Equity—$26M$24M$15M$13M$18M$18M$11M$26M
Total assets—$92M$76M$32M$25M$27M$26M$17M$28M
Shares (diluted)33M27M26M26M25M25M21M18M6M

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin69.2%53.5%60.0%66.6%67.4%87.1%-1018.0%52.8%—
Operating margin28.8%-1.1%-6.7%-3.8%-38.9%-6.9%-69515.4%-1939.6%—
Net margin35.3%-5.8%-9.8%-3.0%-42.4%-8.9%-71717.9%-1910.3%—
FCF margin27.1%12.8%2.4%21.5%22.5%-21.7%-57425.6%-1993.9%—
ROIC—-1.2%-3.8%-4.5%-44.3%-6.5%-88.3%-97.3%-31.0%
ROE—-17.6%-15.7%-6.0%-69.0%-11.1%-158.7%-173.7%-48.4%

Frequently asked questions

What is Eton Pharmaceuticals’s annual revenue?

$80M in fiscal 2025 and $141M over the twelve months to September 30, 2026.

How much profit does Eton Pharmaceuticals make?

Net income was -$5M in fiscal 2025 (net margin -5.8%).

Is Eton Pharmaceuticals’s revenue growing?

Yes: revenue rose 104.9% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.